Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-targeted Therapy" in Breast Cancer.

Centre Jean Perrin

Status and phase

Completed

Phase 2

Conditions

Breast Cancer

Treatments

Drug: Docetaxel

Drug: Cetuximab

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00600249

TENEO

Details and patient eligibility

About

The purpose of this study is to assess the pathological response rate in operable breast cancer patients treated by neoadjuvant combination "Taxotere-Erbitux".

Enrollment

35 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

§ Age > or equal to 18 years.§
Performance status inferior or equal to 1 (WHO criteria)
Histologically proven breast cancer, non metastatic, with clinical tumor diameter > or equal to 2 cm.
HR negative and HER 2 negative.
Clinical stage II and IIIa.
Non prior treated patients either by surgery, radiotherapy, hormonotherapy or chemotherapy.§
Adequate hematological, renal and hepatic functions : neutrophils > 2.109 /L, platelets > 100.109 /L, Hb > 10 g/dL, normal bilirubin, ASAT and ALAT inferior or equal to 2,5 ULN (upper normal limit), alkaline phosphatases £ 2,5 ULN, creatinine < 140 µmol/L or creatinine clearance > 60 mL/min.§
Written informed consent§
Affiliation with social security system (or profit being of such a mode) according to terms' of the law of August 9, 2004.

Exclusion criteria

Male patient.
Pregnant or lactating women or childbearing potential with no efficacy contraception.
Other breast cancer form and particularly inflammatory form and/or negliged (T4b or T4d).§
Non measurable tumor.
Prior surgery or primary axillary dissection.
Prior treatment for this new breast cancer.
Under guardianship patient
Patient with antecedent of second cancer, excepted in situ uterine carcinoma or baso-cellular cutaneous cancer considered as definitively cured.
Patient with an associated pathology considered incompatible with the study.§ Cardiac, renal, medullar, respiratory or hepatic insufficiency.
Significant neurological or psychiatric troubles.§ Symptomatic or evolutive troubles in CNS or metastasis.
Peripheral neuropathy > grade 2 NCI-CTC (version 3.0)
Previous allergy with polysorbate 80.
Concomitant treatment with a drug tested in a clinical trial, participation to another clinical study, for the last thirty days or prior chemotherapy.
Patients non stable for the following 6 months or leaving at a great distance of the participating center.